ORIC Pharmaceuticals, Inc.ORICNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P15
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -10.14% |
| Q3 2025 | -5.81% |
| Q2 2025 | 23.98% |
| Q1 2025 | -22.93% |
| Q4 2024 | 2.46% |
| Q3 2024 | 7.82% |
| Q2 2024 | 31.79% |
| Q1 2024 | -10.30% |
| Q4 2023 | 9.35% |
| Q3 2023 | 19.17% |
| Q2 2023 | -3.74% |
| Q1 2023 | 19.77% |
| Q4 2022 | 10.68% |
| Q3 2022 | 6.43% |
| Q2 2022 | -17.79% |
| Q1 2022 | 0.50% |
| Q4 2021 | 29.82% |
| Q3 2021 | -16.87% |
| Q2 2021 | 32.66% |
| Q1 2021 | -3.43% |
| Q4 2020 | 37.16% |
| Q3 2020 | 14.35% |
| Q2 2020 | 6.47% |
| Q1 2020 | 4.22% |
| Q4 2019 | 23.58% |
| Q3 2019 | 11.75% |
| Q2 2019 | -3.30% |
| Q1 2019 | 0.00% |